

Appendix

Comparison of therapeutic efficacy between cTACE and aTACE

	cTACE (38 patients)	aTACE (39 patients)
Complete response rate	47%	90%
Median overall survival period (months)	36 months	53.3 months
Median progression-free survival (months)	10.4 months	21.1 months
Median time to disease progression (months)	10.7 months	24.6 months
Three-year progression-free survival rate	11.9%	38.3%
Adverse event occurrence rate within 30 days of the first treatment		
- Elevation of bilirubin	98%	82%
- Elevation of alkaline phosphatase	87%	80%
- Elevation of alanine aminotransferase	87%	100%
Serious adverse event occurrence rate within 30 days	5.22%	2.34%